Novo Nordisk launches Ryzodeg in India

Ryzodeg offers adults with type 2 diabetes successful reductions in HbA1c1,3,4,5, with lower risk of hypoglycaemia versus biphasic insulin aspart 303,4. 

 

As Ryzodeg is a combination product it requires fewer daily injections than administering basal and mealtime insulin in separate injections.

 

People with diabetes currently using basal-bolus regimens may need to take up to four daily injections, which can be inconvenient and stressful. Ryzodeg provides successful glycaemic control, fewer injections and reduced rates of hypoglycaemia compared to basal-bolus regimens.

 

Mads Bo Larsen, Corporate Vice President for Business Area Africa, Gulf & India, Novo Nordisk said, “India has close to 65.1 million people with diabetes standing second in the world map. We are focused at providing quality medications that will help health care professionals to meet the demands and challenges of diabetes in India. We are extremely pleased to have introduced Ryzodeg™ reinforcing our commitment to provide best of healthcare solutions for the use of doctors in India.”

 

“Novo Nordisk has always been striving to develop products that address key challenges faced by people with diabetes and physicians. For more than 90 years, Novo Nordisk has been leading the fight against diabetes by developing the most innovative products based on patient needs. The launch of Ryzodeg™ builds on this heritage as it is an innovative product that will give the health care professional a better way to manage the condition. In a country like India where diabetes has become one of the biggest healthcare challenges, it is critical that product innovations are aimed at assisting physicians to  provide better and effective treatment options,” said Melvin Oscar D’souza, Managing Director, Novo Nordisk India.

 

Diabetes is a group of diseases marked by high levels of blood sugar (glucose) caused by problems with the body’s ability to produce or properly use insulin, or both.  

 

Type 2 diabetes is a progressive disease6, which means some patients will need to eventually advance insulin treatment by adding mealtime insulin – bolus therapy – to achieve or maintain their glycaemic targets over time6. Studies have shown that more than 50% of people with type 2 diabetes on basal insulin do not achieve their glycaemic targets 7,8,9.

 

Complications from diabetes caused by failing to keep optimal glycaemic control can be serious, and may include problems such as heart disease, stroke, blindness, kidney disease, nerve damage and premature mortality10,11. 

 

Ryzodeg is expected to help people with diabetes who were dependent on separate basal and bolus injections in improving their quality of life. However it is important to note that patients must consult their doctor and strictly follow their advice about any change in their treatment as this product has to be prescribed by a qualified physician.